MARKET

TRAW

TRAW

Traws Pharma
NASDAQ
0.6456
-0.0034
-0.53%
After Hours: 0.6351 -0.0105 -1.63% 19:28 05/10 EDT
OPEN
0.6457
PREV CLOSE
0.6490
HIGH
0.6629
LOW
0.6300
VOLUME
32.91K
TURNOVER
0
52 WEEK HIGH
1.450
52 WEEK LOW
0.5509
MARKET CAP
16.33M
P/E (TTM)
-0.7151
1D
5D
1M
3M
1Y
5Y
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Traws Pharma Completes First Cohort Dosed In Phase 1 Trial For COVID Therapy
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers Topline Phase 1 data and Phase 2 initiation expected in H2 2024.
Benzinga · 4d ago
TRAWS PHARMA INC - INVESTIGATIONAL TRAVATRELVIR DEMONSTRATED PRECLINICAL ACTIVITY AGAINST MULTIPLE SARS-COV-2 VARIANTS
Reuters · 4d ago
Weekly Report: what happened at TRAW last week (0429-0503)?
Weekly Report · 5d ago
Weekly Report: what happened at TRAW last week (0422-0426)?
Weekly Report · 04/29 10:03
Weekly Report: what happened at TRAW last week (0415-0419)?
Weekly Report · 04/22 09:59
Traws Pharma Shares Insights on Developments and Health
TipRanks · 04/16 20:24
Earnings Scheduled For April 16, 2024
Traws Pharma is expected to report earnings for its fourth quarter. Bank of America, Johnson & Johnson and Morgan Stanley are expected to also report before the bell. CXApp is likely to report quarterly loss at $0.35 per share on revenue of $1.80 million.
Benzinga · 04/16 10:53
More
About TRAW
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Webull offers Traws Pharma Inc stock information, including NASDAQ: TRAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRAW stock methods without spending real money on the virtual paper trading platform.